Six randomized controlled trials including 860 patients with knee osteoarthritis were included in this systematic review and meta-analysis comparing bone marrow aspirate concentrate (BMAC) injections versus other injectable therapies. Pooled outcomes of interest included overall complication rates, early (≤7 days) complications, late (>7 days) complications, type of complication (pain, effusion, inflammation, stiffness), and number needed to harm (NNH). The pooled results showed no significant difference in overall, early, or late complication rates between BMAC and other injectables. Knee effusion and post-injection pain were the most frequent complications, but most resolved within one week. The authors conclude that BMAC injections have a comparable safety profile to other injectables for knee osteoarthritis, with most complications being mild and self-limiting.